4. Synthesis of APIs and KSM

 

Our research revolves around the development of synthetic procedures for various APIs and KSMs. While developing processes, we mainly focus to utilize indigenous raw materials, wherever possible, to reduce the cost of the target molecule by 20-30% as that of the existing market price.

​

In this direction, we have developed process for Camostat mesylate that acts as a serine protease inhibitor used primarily for the treatment of postoperative reflux esophagitis and for acute exacerbations of chronic pancreatitis. This drug has more than 15 years of clinical practice in Japan with a safe clinical track record. It is a clinically proven serine protease inhibitor, which is active against the enzyme transmembrane protease serine 2 (TMPRSS2) partially blocked SARS-CoV-2 S-driven entry into lungs cells. We have developed an improved and indigenous process for Camostat Mesylate and its two key intermediates. With our intervention, the cost of the final API was significantly reduced.

​

​

​

​

​

​

​

​

​

​

 

 

We have developed the cost-efficient process for 2-cyano-4-methyl biphenyl or ortho-tolylbenzonitrile (OTBN) which is used as a KSM for Sartan drugs. OTBN is primarily imported from China in a relatively higher quantity (Approx. 1000 MT/annum) at a high cost. Our research is devoted to obtain a reliable synthetic process for OTBN using indigenously available cheap raw materials. This would not only reduce the production cost for the KSM but also contribute in making self-reliant India.